HLH

Heart & Lung Health selects Caristo Diagnostics AI technology to provide early diagnosis of coronary artery disease UK-wide

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Lung cancer, Chest pain, Information technology, Radiology, Coronary artery disease, Partnership, Risk, University, Patient, Lung, Calcium, National Health Service, NHS, Research, Hospital, RadNet, Artificial intelligence, Death, Plaque, Artery, Mace, CCTA, Heart, HLH, Health, Medical device

OXFORD, England, March 19, 2024 /PRNewswire/ -- Heart & Lung Health (HLH), a UK-wide network of over 110 expert cardiothoracic radiologists, has partnered with Caristo Diagnostics, a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.

Key Points: 
  • OXFORD, England, March 19, 2024 /PRNewswire/ -- Heart & Lung Health (HLH) , a UK-wide network of over 110 expert cardiothoracic radiologists, has partnered with Caristo Diagnostics , a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.
  • Many will undergo a coronary computed tomography angiography (CCTA) scan to diagnose coronary artery disease caused by plaques that narrow or block the arteries that supply blood to the heart.
  • "Early diagnosis and interventions have the potential to significantly improve health outcomes for thousands of patients at risk of coronary artery disease.
  • We are pleased to announce our partnership with Heart & Lung Health, aiming to enhance accessibility to CaRi-Heart technology for patients throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

Retrieved on: 
Tuesday, January 9, 2024
University, Patient, IEI, Research, DHR, Collection, Health, IDT, RNA, IGI, Science, Tissue, Nobel, Translation, Medicine, University of California, Berkeley, Government, Danaher Corporation, Beacon, Public, Safety, Quality control, FDA, Leica Biosystems, DSM-IV codes, Immunity, Engineering, Leica Microsystems, Brain, Hemophagocytic lymphohistiocytosis, Gene editing, Integrated DNA Technologies, HLH, Medical device

The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.

Key Points: 
  • The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.
  • The collaboration, which enables a substantial new research program at IGI, is the largest Danaher Beacon to date.
  • The Beacons program funds pioneering academic research with the goal of developing innovative technologies and applications for human health.
  • The unique nature of CRISPR makes it ideal for developing and deploying a platform capability for CRISPR cures on demand.

Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Food, HLH, Hemophagocytic lymphohistiocytosis, Euronext Paris, IND, Disease, IPH, Death, IPHA, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND.
  • On October 5, Innate announced that the lacutamab IND has been placed on partial clinical hold by FDA following a recent patient death in the TELLOMAK study.
  • The FDA decision to lift the partial clinical hold is based on the FDA review of the fatal case which Innate, together with a steering committee of independent experts, determined to be related to aggressive disease progression and lacutamab unrelated.
  • “We have worked closely with the FDA to diligently resolve the partial clinical hold on the lacutamab IND, which included an in-depth analysis of the fatal case which was due to progression of an aggressive form of the disease,” said Dr Quaratino, Chief Medical Officer of Innate Pharma.

Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Oncology, Clinical Trials, Assistant, IL2RA, CRP, Safety, C-reactive protein, Therapy, University, ASH, Disease, Patient, Peripheral T-cell lymphoma, Monoclonal antibody, Trial of the century, Prognosis, ORR, MD, HLH, Cancer, SIRP, Doctor of Philosophy, Biomarker, MD Anderson Cancer Center, Society, Pharmaceutical industry, Vaccine, Nursing

Data from ten sHLH patients in the ongoing Phase 1b clinical study showed favorable safety results and overall response rate (ORR) of 70% in all patients dosed with ELA026.

Key Points: 
  • Data from ten sHLH patients in the ongoing Phase 1b clinical study showed favorable safety results and overall response rate (ORR) of 70% in all patients dosed with ELA026.
  • The majority of enrolled patients were difficult-to-treat, malignancy-associated HLH and displayed poor prognostic clinical and biomarker features at baseline.
  • The Phase 1b study is an ongoing open-label, multi-dose, single-arm, multicenter study designed to evaluate the safety and efficacy of ELA026, assess biomarkers and identify a dose for Phase 2/3 testing (ClinicalTrials.gov identifier: NCT05416307 ).
  • “We are extremely encouraged by the data from the first two cohorts, and we look forward to continuing enrollment for this study as we advance the ELA026 clinical program.”

Innate Pharma Provides Update on Lacutamab Clinical Program

Retrieved on: 
Thursday, October 5, 2023
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Food, PTCL, IND, Safety, Patient, IPHA, Cutaneous T-cell lymphoma, Hemophagocytic lymphohistiocytosis, HLH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Euronext Paris, CTCL, IPH, Pharmaceutical industry, Innate Immunotherapeutics

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company’s ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL).

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company’s ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL).
  • The partial clinical hold follows one fatal case of hemophagocytic lymphohistiocytosis (HLH), a rare hematologic disorder.
  • TELLOMAK, Innate Pharma’s ongoing Phase 2 trial of lacutamab in cutaneous T-cell lymphoma (CTCL), completed enrollment in Q2 2023 (n=170 patients).
  • Innate Pharma is on track for final data from the Phase 2 TELLOMAK trial and preliminary data on PTCL in Q4 2023.

UBS Welcomes Clients to New Philadelphia Office

Retrieved on: 
Thursday, August 17, 2023
Finance, Banking, Professional Services, Commercial Building & Real Estate, Construction & Property, Wells Fargo Advisors, Logan Square, Wealth management, BNY Mellon Center (Philadelphia), HLH, Investment, Water, UBS, Town hall, Glass, Financial services, Interior design, Delaware Valley

To support its growing high net worth and ultra-high net worth client base, UBS is continuing to invest in its wealth management business in the Philadelphia area.

Key Points: 
  • To support its growing high net worth and ultra-high net worth client base, UBS is continuing to invest in its wealth management business in the Philadelphia area.
  • Today, the firm announced the opening of its new office at 1735 Market Street, and the hiring of industry veteran David Lojpersberger, who joins the firm’s leadership team in Philadelphia as Market Director.
  • “There is significant wealth creation among high and ultra-high net worth investors in the Philadelphia area,“ said Julie Fox, Philadelphia D.C. Market Executive at UBS Private Wealth Management.
  • Located steps from City Hall and Logan Square, the office is home to the firm’s Private Wealth Management and Wealth Management teams.

Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome

Retrieved on: 
Tuesday, April 4, 2023
Medical Affairs Bureau, Research and development, Swedish Orphan Biovitrum, Pediatrics, Glucocorticoid, Emapalumab, Macrophage, Annals of the Rheumatic Diseases, HLH, MAS, Cincinnati Children's Hospital Medical Center, AOSD, Tocilizumab, Development, Annals, Patient, Division, Bambino, Hospital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Laboratory, Food, Safety, Disease, Pharmaceutical industry, Rheumatology

In the published study, 14 patients with sJIA or AOSD and sHLH/MAS who did not respond to high-dose glucocorticosteroids received emapalumab.

Key Points: 
  • In the published study, 14 patients with sJIA or AOSD and sHLH/MAS who did not respond to high-dose glucocorticosteroids received emapalumab.
  • All 14 patients completed the trial, entered long-term follow-up and were alive at the end of follow-up.
  • Based on the results of this study, Sobi decided to continue to evaluate emapalumab in this patient population and initiated the EMERALD phase 3 study, which is ongoing.
  • “We remain committed to evaluating emapalumab as a potential new treatment option for patients affected by this severe condition.

AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH

Retrieved on: 
Tuesday, March 7, 2023
Data, HLH, Patient, Autoinflammatory diseases, Caregiver, IL18, Safety, Pharmaceutical industry, Medical device

The study is designed to show the efficacy and safety of Tadekinig alfa (r-hIL-18BP) for the treatment of primary monogenic IL-18 driven HLH, an ultra-rare and life-threatening condition with no approved therapies, mainly affecting children.

Key Points: 
  • The study is designed to show the efficacy and safety of Tadekinig alfa (r-hIL-18BP) for the treatment of primary monogenic IL-18 driven HLH, an ultra-rare and life-threatening condition with no approved therapies, mainly affecting children.
  • “This is a truly exciting time as we pioneer development of the first targeted treatment option for IL18 driven diseases and conditions,” said Dr. Djordje Filipovic, CEO of AB2 Bio.
  • “We are pleased to have completed the targeted enrollment in this pivotal study which represents a significant milestone for AB2 Bio and the patient community.
  • “Tadekinig alfa is an important potential new treatment option for patients suffering from IL-18 driven autoinflammatory diseases with no current standard of care.

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium

Retrieved on: 
Thursday, February 16, 2023
CD40, Prostate cancer, IL-6, PSCA, HLH, Patient, Metastasis, Cancer, IMC, RECIST, Sepsis, Aplastic anemia, MYD88, Serum, Hemophagocytic lymphohistiocytosis, CRS, Society, ASCO, Medical imaging, Pharmaceutical industry, Vaccine

HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601. These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients.

Key Points: 
  • The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601.
  • These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients.
  • “We believe these encouraging initial clinical results in mCRPC support the potential of BPX-601 and the GoCAR-T® platform,” stated Rick Fair, President and Chief Executive Officer, Bellicum Pharmaceuticals.
  • GoCAR-T cells are designed to function optimally with repeat dosing of rimiducid to induce the co-activation molecules MyD88 and CD40.

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Retrieved on: 
Wednesday, February 15, 2023
Well, Patent, SARS, Collection, Gram, Infection, Tocilizumab, Acute respiratory distress syndrome, CAR, Immunotherapy, CAPS, De novo, HLH, LPS, Smallpox, Acute pancreatitis, Cancer, NLRP3, CINCA, MAS, Sepsis, Patient, Macrophage activation syndrome, Muckle–Wells syndrome, Inhalation, GPI, Therapy, FCAS, FDA, Hemophagocytic lymphohistiocytosis, Trauma, Severe acute respiratory syndrome outbreak, MWS, Cytokine release syndrome, Malaria, FCU, Vaccine

Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 284985, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.” The patent provides added intellectual property protection in Israel into at least 2037, with claims covering the use of for Allocetra™ for prevention or amelioration of cytokine storms in cancer patients receiving CAR-T therapy, as well as in patients whose cytokine storms result from infectious diseases or non-infectious sources.

Key Points: 
  • Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 284985, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.” The patent provides added intellectual property protection in Israel into at least 2037, with claims covering the use of for Allocetra™ for prevention or amelioration of cytokine storms in cancer patients receiving CAR-T therapy, as well as in patients whose cytokine storms result from infectious diseases or non-infectious sources.
  • CAR T-cells are T-cells that have been genetically modified to include a receptor that allows them to specifically target and destroy cancer cells.
  • While certain CAR T-cell treatments were recently approved by the FDA in several cancer indications, such treatments have been associated in many patients with a side effect named cytokine release syndrome, which describes a collection of potentially severe or life-threatening symptoms that stem from over-activation of immune pathways.
  • Preclinical data indicate that Allocetra™ has the potential to prevent or ameliorate cytokine release syndrome associated with CAR T-cell therapies.